Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of bevacizumab plus fotemustine as first-line therapy in metastatic melanoma
2006-001517-15Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and fotemustine in melanoma, sponsored by Roche. Primary endpoints: Overall response rate, Complete remission and 8 more. Started Jan 2007; status: completed.
02
Drugs
bevacizumabfotemustine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2006-001517-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001517-15.